Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ABL2 | P42684 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31349486 | 0.88 | HCAR1 (0.38) | HCAR1TGFBR1GPR119EPHX2AR | |
| SCHEMBL31349483 | 0.83 | EPHX2 (0.38) | HCAR1TGFBR1GPR119EPHX2LIPE | |
| SCHEMBL31349447 | 0.82 | USP30 (0.42) | HCAR1TGFBR1GPR119EPHX2AR | |
| SCHEMBL31349584 | 0.78 | MAP3K12 (0.36) | GPR119 | |
| SCHEMBL31436512 | 0.74 | ESR2 (0.30) | — | |
| SCHEMBL25316223 | 0.74 | AR (0.42) | ARABL1 | |
| SCHEMBL30507171 | 0.74 | AR (0.42) | ARABL1 | |
| SCHEMBL31349528 | 0.73 | ABL1 (0.42) | ABL1 | |
| SCHEMBL21525068 | 0.73 | TGFBR1 (0.47) | HCAR1TGFBR1RORC | |
| SCHEMBL20444529 | 0.71 | USP30 (0.45) | HCAR1TGFBR1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015104-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |